New Retina Radio by Eyetube

The field of retina has made significant strides when it comes to diversity, equity, and inclusion since Julia A. Haller, MD, penned her inspirational 2015 JAMA Ophthalmology editorial, Cherchez la Femme. The ever-growing body of research on this topic stands as a testament to her commitment to understanding the gaps in diversity, particularly in terms of gender differences in leadership positions...

Reimbursements for vitreoretinal surgery have plummeted in the past decade. How dire is the situation? John Thompson, MD, updates listeners on the trends in Medicare reimbursement for a variety of vitreoretinal surgeries, imaging tests, and E&M visits—all of which have implications for the future of care and access to providers.    After the break, Raymond Iezzi, MD, discusses the risks and benefi...

What are the consequences to intentional suspension of anti-VEGF therapy in wet AMD patients? Join moderator Sruthi Arepalli, MD, and panelists Rebecca Soares, MD, MPH, and Vaidehi Dedania, MD, as they explore the circumstances under which treatment might be suspended, examine a paper that described the consequences of treatment suspension, and review how they approach treatment suspension in thei...

The FARETINA-AMD study group assessed approximately 23,000 patients with wet AMD who had received at least one dose of faricimab (Vabysmo, Genentech/Roche). What have they found? Sophie Bakri, MD, summarizes the findings of an IRIS Registry review, which uncovered data about who has been dosed with faricimab, how frequently extended dosing intervals have been achieved, and whether real-world safet...

They’re here: the 96-week data on aflibercept 8 mg (Eylea, Regeneron) in wet AMD. Jean-Francois Korobelnik, MD, PhD stops by to review the 96-week data from PULSAR. How closely did the 96-week results match those at 48 weeks? And how many patients could be extended to 16-, 20-, or even 24-week intervals?    Also, W. Lloyd Clark, MD, joins the show to discuss home-based OCT-guided management of wet...

How effective is prophylactic laser for preventing fellow eye RT/RRD in patients with lattice degeneration who underwent uncomplicated primary RRD repair? NRR Journal Club with VBS moderator David Xu, MD, and panelists Prethy Rao, MD, and Barton Blackorby, MD, summarize a recent study that explored rates of fellow eye RT/RRD in this patient population by comparing cohorts who did and did not recei...

RGX-314 (Regenxbio) could be a one-time gene therapy that addresses diabetic retinopathy. How did it perform in the phase 2 ALTITUDE study? Mark Barakat, MD, shares 1-year safety and efficacy findings from the first two dosing levels of RGX-314 in patients with DR. What are the data? And what’s coming next?    And Hani Salehi-Had, MD, joins the show to tell us about the findings in the DIAMOND stu...

Do patients with a history of retinal detachment (RD) experience higher rates of postpartum RD based on whether they delivered vaginally or via caesarean section? Join NRR Journal Club with VBS moderator Lediana Goduni, MD, and panelists Matt Starr, MD, and Joshua Uhr, MD, as they recap a new paper on this topic. After the break, the group reviews the limitations of this 30-year retrospective anal...

How do retina specialists manage real-world patients with chronic postoperative inflammation? Host John Kitchens, MD, poses various scenarios to panelists Brian Do, MD, and Katherine Talcott, MD, to better understand their approaches to controlling postoperative inflammation in a variety of patients. After the break, the group focuses on the real-world use of long-term steroid-eluting options in t...

Researchers performed a cost analysis of the DRCR Retina Network’s Protocol AC study comparing on-label and off-label anti-VEGF use in DME therapy. What did they determine? Moderator Priya Vakharia, MD, invites panelists Sruthi Arepalli, MD, and Vaidehi Dedania, MD, to review the details of this economic examination. After the break, they explore how studies such as this one affect policy and prob...

How do retina specialists introduce new therapies to patients, and how does thoughtful use of imaging help providers integrate new treatments into their clinics? Moderator Aleksandra Rachitskaya, MD, joins panelists Mrinali Gupta, MD, and Katherine Talcott, MD, to review how innovations in imaging software have helped onboard GA therapies in real-world clinics. This episode is sponsored by ZEISS.

In part 2 of this special podcast interview with John W. Kitchens, MD, and Kirk Packo, MD, FACS, they dive into Dr. Packo's involvement in the creation of AAO subspecialty day, his passion for honoring the history of retina, and his assistance in advocating for vitreoretinal surgery improvements.  This podcast is editorially independent.

John W. Kitchens, MD, interviews Kirk Packo, MD, FACS, around his triumphant career and his decision to retire from practicing medicine following an unexpected diagnosis. In part 1 of 2, Dr. Packo describes his early career goals, his experience with residency matching, his background in acting and directing, and his passion for educating.  This podcast is editorially independent.

How do retina specialists manage patients who present with postoperative inflammation following cataract surgery? Host John Kitchens, MD, and panelists Vaidehi Dedania, MD, and David Eichenbaum, MD, explore the role steroids play in inflammation reduction and examine whether and why extended-release steroids are needed. After the break, Dr. Kitchens quizzes the panelists on their use of specific s...

What did a meta-analysis of studies assessing the safety and efficacy of vitrectomy for diabetic tractional retinal detachment (TRD) find when it comes to the rate of retinal reattachment and final visual acuity? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, outline the top-line findings of this meta-analysis, explore why the study's conclusions brush...

New Retina Radio was at ASRS 2023 to cover the stories you may have missed.    How did patients fare in the GALE extension study, which assessed the safety and efficacy of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) for geographic atrophy? Nathan C. Steinle, MD, shares the results of the first 6 months of GALE, in which patients who received treatment for 24 months in DERBY/OAKS continued wit...

What are the first steps retina specialists should take when a patient presents with postoperative inflammation? Host John Kitchens, MD, is joined by panelists Lisa Faia, MD, and Daniel Kiernan, MD, to debut the NRR miniseries "New Approaches to Chronic Postoperative Inflammation." They review which initial evaluation steps are most useful, discuss the wide range of preventive and treatment strate...

As we enter the therapeutic era of geographic atrophy, imaging the disease is more important than ever. How are retina specialists navigating this new clinical dynamic? Moderator Rishi P. Singh, MD, is joined by Roger A. Goldberg, MD, MBA; Mrinali Gupta, MD; and Katherine Talcott, MD, as they examine which imaging modalities are best suited for busy clinics, discuss how software can facilitate lon...

New Retina Radio was at ASRS 2023 to cover the stories you may have missed.    How often do patients return to the clinic on time for anti-VEGF injections? Christina Y. Weng, MD, MBA, and her team explored how often patients missed scheduled appointments, by how much, and whether missing appointments affected patient outcomes.    And Nikolas JS London, MD, joined us in our mobile studio in Seattle...

How often did human graders agree with software designed to detect and quantify retinal fluid in wet AMD patients using a home OCT prototype? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to examine how reliable such software was in a prospective observational study. After the break, the group speculates how these new data may affect retina doctors'...

Were fluid-free visits correlated with outcomes in the HAWK/HARRIER studies? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, summarize data from a study examining this question, review what it means to be "free of fluid," and discuss how these data fit into the overall conversation about fluid toleration in wet AMD. 

Is a solution to extending duration with aflibercept (Eylea, Regeneron) in DME patients an 8-mg dose rather than the typical 2-mg dose? Diana Do, MD, joined us to review data from the PHOTON study, which assessed the safety and efficacy of high-dose aflibercept in DME patients.   And we hear from Jennifer Lim, MD, who summarized data on extending treatment intervals in the phase 3 YOSEMITE and RHI...

How are doctors using faricimab (Vabysmo, Genentech/Roche) in real-world settings? The IRIS Registry has a few answers. We sat down with Durga Borkar, MD, MMCi, to hear what researchers in the FARETINA-AMD study group found regarding dynamics related to faricimab’s use in wet AMD patients since its approval in January of last year.    We also interviewed Varun Chaudhary, MD, to learn specifically...

After years of failed clinical trials, we finally have an approved therapy for geographic atrophy, and more are hopefully on the way. Allen C. Ho, MD, and Robert L. Avery, MD, sit down with Eleonora M. Lad, MD, PhD; Jeffrey S. Heier, MD; and Dilsher Dhoot, MD, to discuss the introduction of geographic atrophy therapies into the retina clinic.

What did an analysis of the Korean National Health Insurance Service database reveal about the link between age-related macular degeneration and depression risk? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to summarize the study's findings. After the break, the discussion turns to whether depression screening should (or could) occur in retinal clin...